RxDoctor Payments Data

John Lien, MD

Cardiovascular Disease · San Jose, CANPI 1932291648

Payments from drug & device makers

$31,757in general payments, 2019–2025

Across 478 payments — averaging $66.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$10K
  • Boston Scientific$7K
  • Biotronik Inc.$2K
  • Lilly USA, LLC$2K
  • Medtronic$1K
  • Amarin Pharma, Inc.$1K
  • plus $8K from 25 others

What the payments were for

  • Consulting fees$1,1254%
  • Speaking & faculty fees$13,78843%
  • Travel & lodging$2,6748%
  • Food & beverage$13,54743%
  • Education$6242%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,757 in reported general payments places this provider in the 85th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$769,540
Medicare patients
719
Services billed
3,279

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban730$727,373
XareltoRivaroxaban329$297,433
EntrestoSacubitril/Valsartan187$225,564
JardianceEmpagliflozin127$146,993
FarxigaDapagliflozin Propanediol129$126,830
VascepaIcosapent Ethyl163$102,861
BrilintaTicagrelor109$64,457
Repatha SureclickEvolocumab69$50,064
VerquvoVericiguat41$44,026
RybelsusSemaglutide17$37,879
Icosapent Ethyl83$36,274
Synjardy XrEmpagliflozin/Metformin Hcl40$26,826
OzempicSemaglutide26$23,986
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide373$17,555
Metoprolol Succinate830$12,730

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$153$727,373730 claims
Johnson & JohnsonXarelto$495$297,433329 claims
NovartisEntresto$566$225,564187 claims
AstraZenecaFarxiga, Brilinta$880$191,287238 claims
Boehringer IngelheimJardiance, Synjardy Xr$10,177$173,819167 claims
Novo NordiskRybelsus, Ozempic$1,050$61,86543 claims
MerckVerquvo$1,094$44,02641 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in San Jose

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →